Merck Says Investigational Skin Therapy Shows Potential

Merck & Co Inc. (NYSE:MRK) on Wednesday presented initial results from its Phase 2b MK-7240-012 trial at the European Academy of Dermatology and Venereology (EADV) 2026 Congress. Phase 2b Trial Delivers Positive Results The study evaluated tulisokibart—an investigational monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A)—in patients with moderate to severe hidradenitis suppurativa. The trial met its primary endpoint of Hidradenitis Suppurativa Clinical Response 50 (HiSCR